Minimal Residual Disease Market

The Minimal Residual Disease (MRD) market consists of diagnostic tests used to detect small numbers of cancer cells remaining in a patient after treatment, helping to guide further therapy and predict relapse. The primary customers are hospitals, specialty clinics, and laboratory centers. Key growth drivers include the rising prevalence of cancer, increased healthcare spending, growing awareness of personalized medicine, and technological advancements in diagnostic techniques.